Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Can you name major firms in canakinumab's biosimilar industry?

Canakinumab and the Biosimilar Landscape

Company Current Status What They’re Doing (if known)
Novartis Owner of Ilaris® (canakinumab) Protects the brand through patent‑and‑regulatory exclusivity; no approved biosimilar yet.
Sanofi No approved biosimilar Has a portfolio of biologics and a strong R&D pipeline; has not yet announced a canakinumab biosimilar, but is actively working on IL‑1β‑targeting antibodies.
Pfizer No approved biosimilar Known for large biologics program; has been exploring IL‑1 antagonists in pre‑clinical and early‑phase studies.
Amgen No approved biosimilar Actively pursuing antibody‑based therapies; has announced early‑stage IL‑1β inhibitors that could evolve into a biosimilar.
Biogen No approved biosimilar Has a sizable monoclonal antibody portfolio; no public canakinumab biosimilar pipeline.
Roche (Genentech) No approved biosimilar Their antibody division focuses on new therapeutic antibodies; no current canakinumab biosimilar announcements.
GSK No approved biosimilar Engaged in biologic development; no public canakinumab biosimilar pipeline.
Johnson & Johnson (Janssen) No approved biosimilar Strong biologics platform; no canakinumab biosimilar reported.
Celltrion No approved biosimilar Global biosimilar leader; has developed many monoclonal‑antibody biosimilars, but none for canakinumab yet.
Samsung Bioepis No approved biosimilar Similar to Celltrion, focuses on antibody biosimilars; no canakinumab biosimilar announced.
Cangene No approved biosimilar Smaller biologics company; no canakinumab biosimilar in development.

Key Take‑aways

  1. No Approved Canakinumab Biosimilar Yet
    As of now, the only commercially available product that targets interleukin‑1β is Novartis’ Ilaris®. No company has received regulatory approval for a biosimilar version of canakinumab.

  2. Patent Horizon
    Canakinumab’s patents are set to expire in the mid‑2030s (exact dates depend on the region). The window for biosimilar entry is still several years away, which explains why many firms have not yet committed to a development program.

  3. Potential Future Developers
    The major biologics players listed above—especially Amgen, Pfizer, and Sanofi—have the capacity and the antibody‑focused R&D programs that could position them to pursue a canakinumab biosimilar once the patent protection lapses.

  4. Monitoring the Pipeline
    If you’re interested in a canakinumab biosimilar, the best bet is to keep an eye on the annual pipeline reports from these companies. They typically disclose any new antibody‑based projects in their research & development (R&D) updates, investor presentations, and regulatory filings.

Feel free to ask if you want a deeper dive into any of these companies’ biologics portfolios or the regulatory steps involved in bringing a biosimilar to market!



Other Questions About Major :

What major organs can lipitor severely affect? What are major organs at risk from tylenol? Will at least one major indian pharmaceutical company publicly announce the commercial launch of a generic semaglutide injection for weight loss or diabetes treatment on or before march 23, 2026, as c? Major pharmaceuticals methylprednisolone? Pbm catalyst or earnings beat or guidance raise or fda approval or pdufa or major contract or partnership or m a today? A major challenge faced by indian pharma companies today is? How does pfizer plan to address the potential revenue loss from the expiration of major patents?